YARW today
$12.90-$1.33 (-9.35%)close Nov 20, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourSymmetric Triangle
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $20.65
Key levels
Resistance$24.00
Resistance$19.92
Support$12.38
Latest news & SEC filings
DealYarrow Bioscience wraps up $172.5M share sale
AnalystJefferies starts Yarrow Bioscience coverage with Buy rating and $40 price target
All YARW news →About Yarrow Bioscience
Yarrow Bioscience is a drug developer in the clinical testing phase, working on treatments for inflammation and immune system disorders. Its main candidate, YB-101, is an antibody targeting TSHR for Graves Disease and Thyroid Eye Disease. The company also owns global rights to BET inhibitor compounds, including the oral BD2-selective VYN202 and the topical pan-BD repibresib. Manufacturing is handled by outside contractors, and no products are sold yet.
Based on the company's 10-K filed Feb 27, 2026.
Nasdaq · Healthcare
Yarrow Bioscience, Inc. (YARW)
What Is the Price Target for YARW?
SEPT Low Target
$58.00
SEPT Mid Target
$59.00
SEPT High Target
$60.00
Analyst Consensus
$59.00
Is YARW a Buy or Sell Right Now?
Thesis
- •Revenue growing 13.8% YoY with ACCELERATING trend — accelerating momentum.
Test your own strategy on YARW
Describe your strategy in plain words, then scan, alert, backtest and paper trade it on YARW with SEPT’s own market data.
Start Free Trial →Is YARW Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$59.00
27
Moat Score
NONE
3/9
Piotroski Score
128.6
Altman Z-Score
What Is Smart Money Doing with YARW?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See Smart Money Data →YARW Growth Story
Revenue YoY
13.8%
3yr Revenue CAGR
6.1%
EPS Growth YoY
33.33%
FCF Growth YoY
2.8%
Revenue Trend
ACCELERATING
Dark Pool Trades for YARW
PREVIEWRecent off-exchange (dark pool) prints for YARW: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:48:29 | $14.16 | 1,000 | $$14K | BUY |
| 16:53:42 | $14.22 | 1,200 | $$17K | BUY |
| 16:53:39 | $14.19 | 1,752 | $$25K | SELL |
| 16:29:06 | $14.23 | 7,933 | $$113K | SELL |
| 15:35:08 | $13.93 | 1,735 | $$24K | MIDPOINT |
5 dark pool trades shown · $$193K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About YARW
3 postsSEPT Investing hosts an active trader community sharing real-time analysis, trade setups, and market discussion for YARW. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
$YARW: Logos Global Management LP and affiliates filed a Schedule 13G/A on Tue Nov 17, reporting beneficial ownership of about 9.99% of Yarrow Bioscience common stock, shares plus prefunded warrants u...
$YARW: ADAR1 Capital Management, LLC and its sole manager Daniel Schneeberger filed an amended Schedule 13G on Mon Nov 16, reporting beneficial ownership of 282,996 shares, or 2.5%, of Yarrow Bioscien...
$YARW: venBio Global Strategic Fund V, L.P. filed a Schedule 13G/A on Mon Nov 16 reporting beneficial ownership of approximately 9.99% of common stock, per the filing. 📄
Join traders discussing YARW in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Yarrow Bioscience, Inc. (YARW) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Your strategy, tested before real money.
Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.
Try SEPT Free for 7 Days →YARW — frequently asked questions
What is YARW stock price today?
Yarrow Bioscience, Inc. (YARW) is at $12.90, down 9.35% (-$1.33) at the Nov 20, 2026 close.
Why is YARW stock moving today?
Latest YARW news — Nov 16, 2026: Yarrow Bioscience wraps up $172.5M share sale · Nov 16, 2026: Jefferies starts Yarrow Bioscience coverage with Buy rating and $40 price target
What is the YARW price target?
The average analyst price target for YARW is $59.00, ranging from $58 to $60, based on 2 analysts. Latest: Guggenheim initiates on Nov 6, 2026.
What do analysts rate YARW?
Analyst ratings for YARW: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did YARW beat earnings?
YARW last reported on Aug 13, 2026: EPS -$2.14 vs -$11.00 expected — a beat of 80.5%.
How much debt does YARW have?
Yarrow Bioscience, Inc. reported $0M of debt and $23M of cash (Jun 30, 2026).
What are YARW support and resistance levels?
Support: $12.38. Resistance: $19.92, $24.00, $27.31.
What are insiders doing with YARW?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on YARW?
Nov 16, 2026: Yarrow Bioscience wraps up $172.5M share sale · Nov 16, 2026: Jefferies starts Yarrow Bioscience coverage with Buy rating and $40 price target